Surmodics, Inc.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It …
Medical - Devices
US, Eden Prairie [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Surmodics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | 0.8800 | 0.780 | 57 | 51 | 12 | 10 | 21 | 18 | 18 | 16 | 15 | 13 |
| 2015 | - | 0.960 | - | 59 | - | 8 | - | 15 | - | 13 | - | 12 |
| 2016 | 0.7700 | 1.005 | 71 | 69 | 9 | 9 | 26 | 21 | 21 | 15 | 18 | 17 |
| 2017 | 0.3000 | 0.313 | 73 | 70 | 3 | 7 | 12 | 53 | 6 | 18 | 20 | 23 |
| 2018 | -0.3400 | 0.417 | 81 | 80 | -4 | 5 | -1 | 3 | 0.24 | -3 | 24 | 27 |
| 2019 | 0.5700 | 0.668 | 100 | 97 | 7 | 11 | 14 | 27 | 7 | 8 | 23 | 53 |
| 2020 | 0.0829 | 0.185 | 94 | 93 | 1 | 2 | 5 | 8 | -1 | 0.94 | 28 | 41 |
| 2021 | 0.3100 | 0.210 | 105 | 104 | 4 | 2 | 12 | 14 | 7 | 2 | 30 | 36 |
| 2022 | -1.9600 | -1.480 | 99 | 133 | -27 | -13 | -12 | 0.22 | -22 | -15 | 46 | 49 |
| 2023 | -0.1100 | -0.260 | 132 | 130 | -1 | 5 | 15 | 0.23 | 5 | -17 | 51 | 57 |
| 2024 | -0.8200 | -0.557 | 126 | 123 | -11 | -7 | 1 | 4 | -5 | -5 | 56 | 46 |
| 2025 | - | -0.240 | - | 140 | - | -3 | - | 5 | - | -6 | - | 53 |
| 2026 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |